27 results about "Human platelet" patented technology

The invention discloses a culture medium for adipose-derived stem cells, and particularly relates to the technical field of stem cell culture. The culture medium comprises a basic culture medium and nerve-vascular niche components, wherein the basic culture medium comprises DMEM / F12, 10% of human-derived platelet lysate and 1% of antibiotic solution; the nerve-vascular niche comprises the following components: a Slit3 recombinant protein, a nerve growth factor-beta, a glial cell-derived neurotrophic factor, a lysyl oxidase inhibitor, dexamethasone, 3-isobutyl-1-methylxanthine and insulin. The traditional fetal calf serum is replaced by the human-derived platelet lysate, so that the risks of immunological rejection and pathogen pollution are avoided; through the synergistic effect of nerve-vessel niche factors, blood vessel maturation and innervation are promoted, programmed mechanical stretching culture is combined, the adipogenic differentiation efficiency of adipose-derived stem cells is remarkably improved, and engineered adipose tissue which is huge in lipid droplet, compact in structure and provided with a nerve-vessel network is formed.

The invention relates to the technical field of cell biology, in particular to an iNKT cell cryopreservation solution and a method for cryopreserving iNKT cells by using the cryopreservation solution. The invention provides an immune cell cryopreservation solution. The immune cell cryopreservation solution comprises human serum albumin, a basic low-temperature protection solution and an optional human platelet lysate. The immune cell freezing medium does not contain animal-derived components except for human bodies, and has the advantages of simple components and good stability. According to the cryopreservation liquid disclosed by the invention, through the combined action of the basic low-temperature protection liquid (such as CryoStor10 (CS10)) and the human serum albumin, the motility rate after cell recovery is improved, and the damage to immune cells (such as iNKT) in the cryopreservation process is reduced. After a small amount of human platelet lysate is further added, the survival rate of cell resuscitation and the amplification capacity can be further improved.

The present application relates to a method for inducing pluripotent cells to proliferate and / or differentiate into megakaryocyte progenitor cells (MKPs), comprising adding a human platelet lysate (hPL) and an HDAC inhibitor to an MKP differentiation medium. The present application also provides a culture medium used in the method, and a composition comprising the culture medium.

To provide safe and high-performance stem cells appropriate for clinical application, and a method for producing the stem cells.SOLUTION: Provided are a stem cell population derived from human deciduous tooth dental pulp, wherein 90% or more of the stem cell population is characterized by being CD117-negative, CD73-positive, CD90-positive, and CD105-positive, and a method for producing a stem cell population derived from human deciduous tooth dental pulp, the method comprising a step of culturing cells isolated from human deciduous tooth dental pulp in a medium that does not contain FBS (fetal bovine serum) in the presence of human platelet lysate (hPL).SELECTED DRAWING: None

Disclosed are methods for selecting, expanding,and / or enriching cells that are resistant to an immunosuppressive agent (e.g., MTX), and the method comprising treating the cells with the immunosuppressive agent and human platelet lysate (HPL). In some embodiments, the cells (e.g., CAR-T cells) can be used for cell therapy.

The present application relates to a method for inducing proliferation and / or differentiation of pluripotent cells into megakaryocyte progenitor cells (MKP), comprising adding human platelet lysate (hPL) and an HDAC inhibitor to an MKP differentiation medium. The invention also provides a culture medium used by the method and a composition containing the culture medium.

The present invention is in the field of in vitro assays, particularly in the field of pyrogen and endotoxin detection. The present invention provides improved compositions suitable for use in animal-free tests, for example, in monocyte activation tests. The improved compositions allow for increased sensitivity, improved dynamic range, and improved fidelity of test responses.

The present invention belongs to the technical fields of biomedicine and molecular biology, and particularly relates to a single-chain fragment variable (scFv) targeting human platelet-derived growth factor receptor (PDGFR)-β and use thereof in chimeric antigen receptor (CAR)-T cell immunotherapy. In the present invention, a scFv sequence targeting a human-derived PDGFRβ antigen is first obtained by immunizing a mouse, and then a second-generation CAR is constructed based on this, and additionally a CAR-T cell is obtained via lentivirus infection. The CAR-T cell can effectively kill a PDGFRβ antigen-positive 293T cell. The present invention provides a brand-new idea for eliminating PDGFRβ-positive cells to treat chronic kidney diseases, chronic liver diseases, cardiovascular diseases and various tumor diseases including various organ fibrosis, and has extremely attractive further development value and application prospects.

Provided is a method for differentiating platelet cells, comprising adding a human platelet lysate (hPL) to a platelet differentiation culture medium. Further provided are a culture medium for differentiating platelets and use thereof.

The present invention is in the field of in vitro assays, particularly in the field of pyrogen and endotoxin detection. The invention provides improved compositions suitable for use in animal-free testing such as for use in a monocyte activation test. The improved compositions allow for test responses with increased sensitivity, improved dynamic range, and improved goodness of fit.

This invention belongs to the field of biotechnology and relates to a method for tracking and assessing the metabolic distribution of platelets in organs based on mitochondrial DNA. Specifically, this invention constructs a humanized mouse model, injects exogenous platelets into the humanized mouse model, and sequences the specific SNVs of the exogenous platelet mitochondrial DNA to trace the metabolic distribution of human platelets or human drug-loaded platelets. The safety is assessed by analyzing the metabolic distribution when human platelets are used as a delivery system.

The invention belongs to the technical field of cell culture, and provides a mesenchymal stem cell 3D culture medium, which comprises a basic culture medium and an additive, the additive is composed of lipid, a metabolism regulator, adherin, a buffering agent and human platelet lysate. According to the mesenchymal stem cell 3D culture medium provided by the invention, through the synergistic effect of all the components, the attachment rate of cells on a microcarrier can be remarkably increased, formation and growth of cell three-dimensional aggregates are promoted, cell senescence can be remarkably reduced, and the proliferation efficiency is improved. In addition, the mesenchymal stem cells obtained through culture of the 3D culture medium can improve the treatment effect on ARDS. The culture medium is simple in component and good in culture effect, and can be widely applied to 3D culture of mesenchymal stem cells of various sources.

The invention discloses a method for efficiently constructing a cell sphere barrier with a specific structure by using a sequential culture medium strategy. The method comprises the following steps: firstly, respectively carrying out cell multiplication culture by adopting respective applicable culture media of mesenchymal stem cells or endothelial cells, and then synchronously or stepwise inoculating the cells by adopting a specific culture medium to carry out three-dimensional cell culture. Then, in a DMEM / F12 culture medium containing human platelet lysates, the human platelet lysates are stably polymerized into cell spheres with specific structures. Due to the specific space structure of the sphere, the sphere has good application potential in the aspects of in-vitro cell migration and invasion research, organoid development, cell barrier mechanism research and the like.

The invention discloses a phototherapy nano system for removing candida and lactobacillus, a preparation method of the phototherapy nano system and application of the phototherapy nano system in preparation of drugs for treating vulvovaginal candidiasis. The phototherapy nano system comprises cell membranes with GPIb, GPIIb / IIIa and gC1q-R / P32 receptors; polylactic acid-glycolic acid copolymer (PLGA) nanoparticles wrapped by a cell membrane; a photosensitizer is embedded on the surface of the cell membrane; the preparation method comprises the following steps: extracting cell membrane PM of human platelets; the method comprises the following steps: premixing an IR780 photosensitizer and a cell membrane PM, and embedding IR780 into the cell membrane PM through ultrasonic under a water bath condition to obtain PM (IR); the preparation method comprises the following steps: carrying out water bath ultrasonic treatment on PM (IR) and polylactic acid-glycolic acid copolymer PLGA nanoparticles, and coating the PM (IR) on the polylactic acid-glycolic acid copolymer PLGA nanoparticles to obtain the PM (IR)-NP bionic nanoparticles. The problems of high recurrence rate, drug tolerance and vaginal flora ecological imbalance in the treatment of the recurrent vulvovaginal candidiasis can be relieved.

The invention discloses colloidal gold chromatography test paper and a kit for detecting platelet CD36 antigen, the colloidal gold chromatography test paper comprises a bottom plate, a sample pad, a gold-labeled combination pad, a nitrocellulose membrane and a water absorption pad, the gold-labeled combination pad is coated with a colloidal gold labeled mouse anti-human CD36 IgG2a monoclonal antibody and a colloidal gold labeled quality control rabbit IgG polyclonal antibody; the nitrocellulose membrane is provided with a detection line coated with a human platelet CD36 antigen capture antibody and a quality control line coated with quality control goat anti-rabbit polyclonal antibody molecules. When the kit is used for detecting the CD36 antigen, a detected sample is fully split by the platelet lysis buffer and then is added into the sample adding hole of the kit, and a detection result can be observed after waiting for 10-15 minutes. By adopting the detection mode provided by the invention, the CD36 antigen on the human platelets can be quickly, simply, conveniently, sensitively and specifically detected.

This invention provides a culture medium for closed-system culture of mesenchymal stem cells, comprising the following components: 1% (v / v) human platelet lysate, 10-15 g / L basal culture medium powder, 15-20 mM HEPES, 1.0-2.0 g / L sodium bicarbonate, and 0.1-1.0 g / L sodium chloride; wherein the basal culture medium powder includes non-essential amino acids, D-glucose, L-glutamine, specific growth factors, inorganic salts, and vitamins. Using the culture medium provided by this invention for mesenchymal stem cell culture eliminates the need for exogenous CO2, reducing equipment costs and process complexity; furthermore, it results in cell viability ≥97%, more concentrated particle size distribution, and more stable expression of surface markers, which is beneficial for large-scale production.

This invention discloses a gel formulation containing human platelet-derived growth factor (PDGF). The components and dosages are as follows: PDGF 50,000-300,000 IU / mL, sodium carboxymethyl cellulose 3.0-4.5%, polyvinyl alcohol 0.5-3%, disodium hydrogen phosphate dodecahydrate 0.258-0.774%, sodium dihydrogen phosphate monohydrate 0.039-0.116%, sodium chloride 0.6-0.95%, methylparaben 0.15-0.18%, propylparaben 0.015-0.020%, and protein protectant 0.4-0.6%. This invention, through optimization of the gel matrix combination and ratio, enables the gel to possess excellent stability and skin adhesion, improves the biological activity of the formulation, and promotes cell proliferation and wound repair at the wound site. It also offers advantages such as a pleasant user experience and simple processing.

Methods provided for producing human platelet lysates (HPL) typically from expired platelet units that were initially manufactured to be infused into patients. Whole blood units from which platelets will be prepared for transfusion are maintained at a temperature cooling toward room temperature. The platelet lysate produced by the method can be formed from platelets that have been removed from the refrigerated whole blood unit more than 8 hours after phlebotomy.

The invention discloses a recombinant platelet-derived growth factor gel. The prescription is optimized in multiple dimensions by reducing the types of auxiliary materials of the gel, adjusting a buffer system, the concentration of salt ions and the ratio of the gel matrix to the recombinant human growth factor, so that the adhesion capacity of the gel on the skin is improved, the stability of the gel is improved, the biological activity stability is ensured, and the bioavailability of the gel is improved. Meanwhile, due to the reduction of the auxiliary materials, the production cost and the quality control difficulty are reduced, and the risk of preparation impurities is reduced.

The present application relates to a method for amplifying / culturing pluripotent stem cells, comprising culturing pluripotent stem cells in a pluripotent stem cell culture medium under suspension culture conditions, the pluripotent stem cell culture medium comprising a basal culture medium, human platelet lysates, and addition factors thereof. The invention also provides application of the pluripotent stem cell and the pluripotent stem cell culture medium.

The invention relates to the technical field of cell biomedicine, in particular to umbilical cord mesenchymal stem cells with high PD-L1 expression, a culture method and application of the umbilical cord mesenchymal stem cells and a method for promoting PD-L1 expression through in-vitro energization. The umbilical cord mesenchymal stem cell in-vitro energizing inducer is based on a DMEM / F12 culture medium containing 3%-7% of human platelet lysis buffer, and further comprises the following components: a tumor necrosis factor alpha, interferon gamma, human serum albumin, transferrin, insulin, riboflavin, N-acetylcysteine and a vascular endothelial growth factor. The in-vitro energizing inducer reduces the content of a stimulating factor tumor necrosis factor alpha and interferon gamma, reduces immunogenicity abnormity caused by TNF-alpha, remarkably improves PDL1 expression and provides a basis for inflammation treatment. The influence of long-time stimulation on cell functions and activity is remarkably reduced through short-time factor-induced stimulation.

The present application relates to the technical field of medical quality control products, in particular to a quality control substance for lymphocyte subset analysis and a preparation method thereof, comprising human monocyte simulation particles, human granulocyte simulation particles, human lymphocyte simulation particles, human red blood cell simulation particles, human platelet simulation particles and a preservative, wherein the human monocyte simulation particles, the human granulocyte simulation particles, the human lymphocyte simulation particles, the human red blood cell simulation particles and the human platelet simulation particles are added into the preservative, and mixed according to the concentration of human particles to obtain the quality control substance for lymphocyte subset analysis. Compared with the prior art, the quality control substance for lymphocyte subset analysis and the preparation method thereof have the advantages of simple operation, small batch difference and good stability, and can be applied to the field of quality control of flow cytometry methodological lymphocyte subset analysis.

The application discloses an anti-platelet GPIb-IX antibody and application thereof, and belongs to the technical field of biological medicines. The application selects the starting signal protein GPIb-IX of arterial thrombosis as a target, and prepares an anti-human GPIb-IX humanized antibody. Specifically, human platelets are used as antigens to immunize mice, and a mouse-derived anti-human GPIb-IX antibody is obtained through screening and preparation, a humanized anti-GPIb-IX antibody ATHA is constructed by mutating a human-derived sequence, the heavy chain variable region of the ATHA comprises a VH-CDR3 shown in SEQ ID NO. 1, and the light chain variable region comprises a VL-CDR3 shown in SEQ ID NO. 2. The Fab segment of the ATHA can effectively inhibit platelet activation mediated by the GPIb-IX receptor, inhibit thrombosis in the body without accompanying side effects such as platelet reduction and bleeding, and has the characteristics of high specificity, good safety and small side effects. Meanwhile, the ATHA can remove platelets. Therefore, the ATHA-Fab has clinical value as a new anti-thrombotic drug, and can be used for treating diseases related to arterial thrombosis. The ATHA can remove platelets, and can be used for treating diseases with increased platelet quantity or removing platelets in the body.

Inventors show that both iKO and Eng+ / - experienced increased bleeding compared to WT mice (longer bleeding times, more rebleeding events, greater hemoglobin loss, p<0.05). Treatment with pEng effectively reduced bleeding in all genotypes (p<0.05), reverting to the control WT condition. Furthermore, pEng induced strong platelet aggregation in both murine and human platelets compared to controls (p<0.01), demonstrating its efficacy in promoting hemostasis. No differences were found in term of co-culture, wound healing and sprouting considering controls and endoglin siRNA ECs, while a beneficial effect on ENG-free endothelial cells was found in capillary flow conditions, restoring the control condition. Accordingly, pEng appears to be a promising treatment for epistaxis in HHT, without deleterious effect on EC tested functions. The present invention relates to a peptide derived from endoglin (pEng) comprising at least the amino acid sequence X1-X2-X3-X4-X5-X6-X7-X8-X9-X10 (SEQ ID NO: 1) wherein X1 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), X2 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), X3 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), X4 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), X5 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), X6 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), X7 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), X8 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), X9 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), X10 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), Wherein peptide derived from endoglin (pEng) comprises at least one of each Phe(F), Leu(L), Tyr(Y), His(H), Thr(T), Ser(S), and Val(V).

The invention discloses a culture medium and a culture method for selectively amplifying NK (Natural Killer) cells. The culture medium for selectively amplifying the NK cells comprises a KBM581 basal culture medium and an additive, and the additive comprises the following components in concentration: 500IU / mL of IL-2, 25ng / mL of IL21, 20ng / mL of IL15, 1ug / mL of OK432, 10% of human platelet lysate and 0.05 ug / mL-20ug / mL of dexamethasone sodium phosphate injection. According to the culture method for selectively amplifying the NK cells, the culture medium for selectively amplifying the NK cells is adopted, coating, cell sorting and feeder layer cells are not needed, and operation is easy. After the culture medium and the culture method for selectively amplifying the NK cells are used for culturing for 2 weeks, the amplification multiple of the NK cells can reach 200 times, the proportion of the NK cells reaches 90% or above, the viability of the NK cells reaches 95% or above, and the NK cells are stable in batches and can meet clinical requirements.

Provided is the use of human platelet-derived apoptotic vesicles in the preparation of a formulation for promoting osteogenic differentiation of mesenchymal stem cells. Further provided is a bone defect repair formulation, comprising a PLGA scaffold material, wherein the human platelet-apoptotic vesicles are loaded on the surface of the PLGA scaffold material.